Cargando…

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC

SIMPLE SUMMARY: Non-small-cell lung cancer (NSCLC) patients become resistant to targeted therapies such as tyrosine kinase inhibitors (TKIs) through mutations in the EGFR gene and by overexpression of proteins such as p120-catenin and PRMT-1. We studied EGFR wild-type and mutated EGFR in parental an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Racherla, Kavya Sri, Dovalovsky, Katrina, Patel, Meet, Harper, Emma, Barnard, Jacob, Nasifuzzaman, S M, Smith, Mason, Sikand, Riya, Drinka, Eva, Puri, Neelu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340662/ https://www.ncbi.nlm.nih.gov/pubmed/37444572 http://dx.doi.org/10.3390/cancers15133461

Ejemplares similares

Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
por: Rager, Taylor, et al.
Publicado: (2022)

PRMT5 promotes chemotherapy‐induced neuroendocrine differentiation in NSCLC
por: Shen, Qi, et al.
Publicado: (2023)

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
por: Ntzifa, Aliki, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer
por: Huang, Jianhao, et al.
Publicado: (2021)

Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib
por: Fan, WuQiang, et al.
Publicado: (2019)

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
por: Crowley, Fionnuala, et al.
Publicado: (2021)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
por: Zhai, Xiaoyang, et al.
Publicado: (2021)

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
por: Schrank, Zachary, et al.
Publicado: (2018)

Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification
por: Ito, Tatsuo, et al.
Publicado: (2009)

Resistance to Molecularly Targeted Therapies in Melanoma
por: Patel, Meet, et al.
Publicado: (2021)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
por: Gerber, David E., et al.
Publicado: (2022)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

PRMT5 facilitates angiogenesis and EMT via HIF-1α/VEGFR/Akt signaling axis in lung cancer
por: Zheng, Yonghua, et al.
Publicado: (2023)

Cardiac Safety of Osimertinib: A Review of Data
por: Ewer, Michael S., et al.
Publicado: (2021)

PRMT1 loss sensitizes cells to PRMT5 inhibition
por: Gao, Guozhen, et al.
Publicado: (2019)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
por: Han, Rui, et al.
Publicado: (2020)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
por: Su, Po‐Lan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rat81b3jomqddihsugcg9rknd9